Recruiting

CAR Therapy & Radiation

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04888338

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Data Capture

Electronic Medical Record

Study Details

Brief summary:

This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. Collecting information from patients before, during, and after receiving chimeric antigen receptor therapy or radiation therapy may help doctors to optimize patient selection, dose, timing, and sequencing of these treatments.

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Study ID

NCT04888338

Start date

Apr 10, 2021

Status verified date

Apr, 2026

Completion date

Nov 14, 2026

Anticipated

Primary completion date

Nov 14, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 18 years or older
  • Treatment with or intention to treat with radiation therapy, standard-of-care CAR-T cell therapy and/or standard-of-care bispecific therapy, within a 90 day window for a hematologic malignancy

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational (data collection)

Patients medical records are reviewed for details about CAR-T and RT treatment and acute and late toxicities, disease outcomes such as any events related to local or distant disease progression, survival, and cause of death if available. Patients' imaging scan data is collected at baseline, within 2 months of the first treatment of RT or CAR-T, and at 3, 6, 12 months, and then annually for 5 years after RT completion.

Interventions

Data Capture

Treatment related data is collected

Electronic Medical Record

Medical records are reviewed

Primary outcome measure

  • Clinical outcomes of patients with hematologic malignancies receiving standard-of-care chimeric antigen receptor therapy (CAR-T) and radiation therapy (RT) [ Time Frame: Up to 5 years ]

Central Contacts and Locations

Central contacts

Penny Q Fang, MD

713-563-2345pfang@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Penny Q. Fang, MD

832-260-1389pfang@mdanderson.org

Principal Investigator:

Penny Q. Fang, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Apr 16, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-04-16.